ASAryana Sepassi

Aryana Sepassi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aryana Sepassi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Bounthavong

    University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA

    5 shared publications
  • Jonathan H. Watanabe

    Associate Dean of Assessment and Quality, Professor of Clinical Pharmacy, Department of Clinical Pharmacy Practice, University of California, Irvine School of Pharmacy and Pharmaceutical Sciences, Irvine, CA, USA

    4 shared publications
  • Mark Bounthavong

    Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, La Jolla, USA

    3 shared publications
  • Britney Stottlemyer

    School of Pharmacy, University of Pittsburgh, 6399 Salk Hall, 3501 Terrace St, Pittsburgh, PA, 15261, USA

    2 shared publications
  • Cathy Logan

    Associate Professor of Medicine, Division of Infectious Diseases and Global Health, University of California, San Diego, La Jolla, CA, USA

    2 shared publications
  • Meng Li

    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, USA

    2 shared publications

Latest Publications

  • Open Access

    COVID-19 vaccine acceptance differences among unvaccinated foreign- and united states-born persons: A cross-sectional study, 2021

    by Aryana Sepassi, Samantha Garcia, Sora Tanjasiri, Sunmin Lee, Nana Entsuah-Boateng, Mark Bounthavong


  • Open Access

    Association of Opioid and Concurrent Benzodiazepine, Skeletal Muscle Relaxant, and Gabapentinoid Usage on Healthcare Expenditure and Resource Utilization: A Serial Cross-Sectional Study, 2009 to 2019

    by Aryana Sepassi, Meng Li, Kangho Suh, Britney Stottlemyer, Mark Bounthavong

    Background: Healthcare providers may be utilizing central nervous system (CNS) depressants to reduce opioid use due to recent changes in public policy. Combination use of these agents with opioids increases the risk of respiratory depression and death. Healthcare expenditures by individuals using these drug combinations have not been previously quantified. We sought to characterize healthcare costs and expenditures associated with a population reporting concurrent CNS depressants and opioid use compared with nonopioid analgesics in the United States from 2009 to 2019. Methods: A serial cross-sectional design was used to compare the healthcare expenditures of adult Medical Expenditure Panel Survey respondents who were prescribed nonopioid analgesics, opioids only, opioids/benzodiazepines (BZD), opioids/BZD/skeletal muscle relaxants (SMR), or opioids/gabapentin (gaba) using pooled data from 2009 to 2019. Expenditure (cost and resource utilization) categories included inpatient, outpatient, office-based, and prescription medicine. Average marginal effects were used to compare survey-weighted annual costs and resource utilizations across the groups as compared to nonopioid analgesic respondents, adjusted for covariates. Results: A weighted total of 34 241 838 individuals were identified. Most were opioid-only respondents (46.5%), followed by nonopioid analgesic (43.4%), opioid/BZD (5.3%), opioid-gaba (3.5%), and opioid/BZD/SMR respondents (1.3%). In comparison to the study groups with nonopioid analgesics, opioid-gaba users had the highest significant incremental cost difference among the different pairings (+$11 684, P < .001). Opioid-gaba, opioid/BZD, and opioid/BZD/SMR respondents had significantly higher inpatient, emergency department, and prescription drug costs and use compared to nonopioid analgesic respondents. Opioid-only respondents had higher outpatient and office-based costs and visits compared to nonopioid analgesic respondents. Conclusions: As healthcare providers seek to utilize fewer opioids for pain management, attention must be paid to ensuring safe and effective use of concurrent CNS depressants to mitigate high healthcare costs and burden.


  • Open Access

    Impact of increasing number of mental health conditions on healthcare costs and resource utilization among individuals with type 2 diabetes: a cross-sectional study

    by Mark Bounthavong, Aysell Medina, Brooke M Wallace, Aryana Sepassi, Candis M Morello

    Objectives: To evaluate the association between the number of mental health conditions among individuals with type 2 diabetes (T2D) and healthcare expenditures in the USA. Methods: A cross-sectional study was conducted to evaluate the relationship between multiple mental health conditions (0, 1, and 2 or more mental health conditions) among individuals with T2D on healthcare expenditures using data from the 2019 US Medical Expenditure Panel Survey. Key findings: A total of 24,091,931 weighted individuals with T2D were included for analysis; 76.8% had no co-occurring mental health conditions, 15.5% had one mental health condition, and 7.7% had two or more mental health conditions. Individuals with one and two or more mental health conditions had significantly greater total healthcare costs (+$7135 and +$7168), office-based costs (+$1196 and +$1483), prescription costs (+$2091 and +$3757), office-based visits (+3.55 and +6.46), and prescriptions fills (+13.97 and +26.77) than individuals with no mental health conditions. Conclusions: Individuals with T2D and an increasing number of co-occurring mental health conditions were associated with increased healthcare costs and resource utilization. Underlying mechanisms for this relationship remain unclear, and further investigations are needed to accurately assess the impact this may have on health outcomes.


  • Top Cited Papers
    Open Access

    Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis

    by Aryana Sepassi, Meng Li, Jason A. Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel

    Background: Rural residents have a higher prevalence of colorectal cancer (CRC) mortality compared to urban individuals. Policies have been aimed at improving access to CRC screening to reduce these outcomes. However, little attention has been paid to other determinants of CRC-related outcomes, such as stage at diagnosis, treatment, or survivorship care. The main objective of this analysis was to evaluate literature describing differences in CRC screening, stage at diagnosis, treatment, and survivorship care between rural and urban individuals. Materials and Methods: We conducted a systematic review of electronic databases using a combination of MeSH and free-text search terms related to CRC screening, stage at diagnosis, treatment, survivorship care, and rurality. We identified 921 studies, of which 39 were included. We assessed methodological quality using the ROBINS-E tool and summarized findings descriptively. A meta-analysis was performed of studies evaluating CRC screening using a random-effects model. Results: Seventeen studies reported disparities between urban and rural populations in CRC screening, 12 on treatment disparities, and 8 on staging disparities. We found that rural individuals were significantly less likely to report any type of screening at any time period (pooled odds ratio = 0.81, 95% CI, 0.76-0.86). Results were inconclusive for disparities in staging at diagnosis and treatment. One study reported a lower likelihood of use of CRC survivorship care for rural individuals compared to urban individuals. Conclusion: There remains an urgent need to evaluate and address CRC disparities in rural areas. Investigators should focus future work on assessing the quality of staging at diagnosis, treatment, and survivorship care in rural areas.


  • Open Access

    Effect of Metformin Use on Vitamin B12 Deficiency Over Time (EMBER): A Real-World Evidence Database Study

    by Keri Hurley-Kim, Chuong Hoang Vu, Nhat Minh Dao, Lam Chau Tran, Sarah McBane, Joyce Lee, Aryana Sepassi


  • Open Access

    Predicted Health Literacy Disparities Between Immigrant and US-Born Racial/Ethnic Minorities: a Nationwide Study

    by Aryana Sepassi, Samantha Garcia, Sora Tanjasiri, Sunmin Lee, Mark Bounthavong

    Background: Racial/ethnic minorities in the USA exhibit reduced health literacy (HL) proficiency, leading to increased health disparities. It is unclear how the effect of birth status (immigrant/US-born) affects HL proficiency among racial/ethnic minorities. Objective: To identify the direct, indirect, and total effects of birth status on HL proficiency among a nationally representative population of racial/ethnic minority adults in the USA. Design: A cross-sectional study of 2019 data from the Medial Expenditure Panel Survey. Participants: Participants aged 18 or older reporting as racial/ethnic minorities (Black, Asian, or Hispanic) with non-missing data. Main Measures: We predicted HL proficiency for each participant using a previously published model. Path analysis was used to estimate the direct, indirect, and total effects of birth status on HL proficiency, accounting for several other covariates. Prevalence ratios were estimated using adjusted Poisson regression to evaluate differences in the “Below Basic” HL category. Key Results: An estimated weighted 81,092,505 participants were included (57.5% US-born, 42.5% immigrant). More racial/ethnic minority immigrant participants fell into the lowest category of HL proficiency, “Below Basic” (14.3% vs 5.5%, p < 0.05). Results of the path analysis indicated a significant, negative direct effect of birth status on HL proficiency (standardized coefficient = − 0.24, SE = 0.01, 95%CI: − 0.26, − 0.23) in addition to an indirect effect mediated through insurance status, health-system resource use, and English proficiency. The total effect of birth status on HL proficiency was found to be − 0.29. The immigrant participant group had 81% higher prevalence of falling into the “Below Basic” HL category compared to US-born participants (prevalence ratio = 1.81, 95%CI: 1.52, 2.16). Conclusions: Immigrant status has a strong, negative, direct effect on HL proficiency among racial/ethnic minorities in the USA. This may be a result of barriers that prevent equitable access to resources that improve proper HL proficiency. US policymakers may consider several methods to reduce this disparity at the health-system-, provider-, and patient-levels.


  • Open Access

    Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States

    by Aryana Sepassi, Ila M. Saunders, Mark Bounthavong, Randy A. Taplitz, Cathy Logan, Jonathan H. Watanabe

    Purpose The aim of this study was to assess the cost effectiveness of letermovir prophylaxis with the option for subsequent pre-emptive therapy (PET) for the prevention of cytomegalovirus (CMV) infection compared with a PET-only scenario in adult allogeneic hematopoietic stem cell transplant (allo-HCT) recipients in the United States over a 10-year time horizon. Materials and Methods A publicly available decision tree model was constructed using a commercial third-party payer perspective to simulate an allo-HCT recipient’s clinical trajectory in the first-year post-transplant, followed by entry to a Markov model to simulate years 2 through 10. Clinical inputs and utility estimates were derived from published literature. Costs were derived from published literature and US Department of Veterans Affairs Federal Supply Schedule drug pricing. Outcomes assessed included life expectancy, quality-adjusted life-years (QALYs), direct medical costs, and the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses (PSA) were performed to test the robustness of the findings. Results Compared with PET alone, letermovir prophylaxis was projected to increase life-years per person (4.99 vs. 4.70 life-years), and increase QALYs (3.29 vs. 3.08) and costs (US$83.411 vs. US$70,698), yielding an ICER of US$59,356 per QALY gained. One-way sensitivity analyses indicated our model was sensitive to mortality (ICER: $164,771/QALY) and utility (letermovir ICER: $117,447/QALY; PET ICER: $107,290/QALY) in the first-year post-transplant. In 57.1% of the PSA simulations, letermovir was a cost-effective option using a willingness-to-pay threshold of US$100,000 per QALY. Conclusions Letermovir prophylaxis is cost effective compared with PET alone with a willingness-to-pay threshold of US$100,000 per QALY gained. Sensitivity analysis results indicate future research is required to understand the impact of mortality and quality of life in the first-year post-transplant to arrive at a conclusive decision on letermovir adoption.


  • Open Access

    Risk of Negative Health Outcomes and High Costs for People With Diabetes and Unmet Psychological Needs in the United States

    by Aryana Sepassi, Mark Bounthavong, Renu F. Singh, Mark Heyman, Kristin Beizai, Jonathan H. Watanabe

    Measuring the population-level relationship between compromised mental health and diabetes care remains an important goal for clinicians and health care decision-makers. We evaluated the impact of self-reported unmet psychological need on health care resource utilization and total health care expenditure in people with type 2 diabetes. Patients who reported unmet psychological needs were more likely than those who did not to incur a higher annual medical expenditure, have greater resource utilization, and have a higher risk of all-cause mortality.